Toll like receptors TLR1/2, TLR6 and MUC5B as binding interaction partners with cytostatic proline rich polypeptide 1 in human chondrosarcoma

Karina Galoian, Silva Abrahamyan, Gor Chailyan, Amir Qureshi, Part Hik Patel, Gil Metser, Alexandra Moran, Inesa Sahakyan, Narine Tumasyan, Albert Lee, Tigran Davtyan, Samvel Chailyan, Armen Galoyan

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Metastatic chondrosarcoma is a bone malignancy not responsive to conventional therapies; new approaches and therapies are urgently needed. We have previously reported that mTORC1 inhibitor, antitumorigenic cytostatic proline rich polypeptide 1 (PRP-1), galarmin caused a significant upregulation of tumor suppressors including TET1/2 and SOCS3 (known to be involved in inflammatory processes), downregulation of oncoproteins and embryonic stem cell marker miR-302C and its targets Nanog, c-Myc and Bmi-1 in human chondrosarcoma. To understand better the mechanism of PRP-1 action it was very important to identify the receptor it binds to. Nuclear pathway receptor and GPCR assays indicated that PRP-1 receptors are not G protein coupled, neither do they belong to family of nuclear or orphan receptors. In the present study, we have demonstrated that PRP-1 binding interacting partners belong to innate immunity pattern recognition toll like receptors TLR1/2 and TLR6 and gel forming secreted mucin MUC5B. MUC5B was identified as PRP-1 receptor in human chondrosarcoma JJ012 cell line using Ligand-receptor capture technology. Toll like receptors TLR1/2 and TLR6 were identified as binding interaction partners with PRP-1 by western blot analysis in human chondrosarcoma JJ012 cell line lysates. Immunocytochemistry experiments confirmed the finding and indicated the localization of PRP-1 receptors in the tumor nucleus predominantly. TLR1/2, TLR6 and MUC5B were downregulated in human chondrosarcoma and upregulated in dose-response manner upon PRP-1 treatment. Experimental data indicated that in this cellular context the mentioned receptors had tumor suppressive function.

Original languageEnglish (US)
Pages (from-to)139-154
Number of pages16
JournalInternational Journal of Oncology
Volume52
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

PRP-1 peptide
Toll-Like Receptor 2
Chondrosarcoma
Cytostatic Agents
Neoplasms
Down-Regulation
Orphan Nuclear Receptors
Cell Line
Oncogene Proteins
Mucins

Keywords

  • Chondrosarcoma
  • Galarmin
  • Innate immunity
  • MUC5B
  • PRP-1
  • Receptors
  • TLR1/2
  • TLR6

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Toll like receptors TLR1/2, TLR6 and MUC5B as binding interaction partners with cytostatic proline rich polypeptide 1 in human chondrosarcoma. / Galoian, Karina; Abrahamyan, Silva; Chailyan, Gor; Qureshi, Amir; Patel, Part Hik; Metser, Gil; Moran, Alexandra; Sahakyan, Inesa; Tumasyan, Narine; Lee, Albert; Davtyan, Tigran; Chailyan, Samvel; Galoyan, Armen.

In: International Journal of Oncology, Vol. 52, No. 1, 01.01.2018, p. 139-154.

Research output: Contribution to journalArticle

Galoian, K, Abrahamyan, S, Chailyan, G, Qureshi, A, Patel, PH, Metser, G, Moran, A, Sahakyan, I, Tumasyan, N, Lee, A, Davtyan, T, Chailyan, S & Galoyan, A 2018, 'Toll like receptors TLR1/2, TLR6 and MUC5B as binding interaction partners with cytostatic proline rich polypeptide 1 in human chondrosarcoma', International Journal of Oncology, vol. 52, no. 1, pp. 139-154. https://doi.org/10.3892/ijo.2017.4199
Galoian, Karina ; Abrahamyan, Silva ; Chailyan, Gor ; Qureshi, Amir ; Patel, Part Hik ; Metser, Gil ; Moran, Alexandra ; Sahakyan, Inesa ; Tumasyan, Narine ; Lee, Albert ; Davtyan, Tigran ; Chailyan, Samvel ; Galoyan, Armen. / Toll like receptors TLR1/2, TLR6 and MUC5B as binding interaction partners with cytostatic proline rich polypeptide 1 in human chondrosarcoma. In: International Journal of Oncology. 2018 ; Vol. 52, No. 1. pp. 139-154.
@article{815d1dc1d66b418fbfffbe8d35aea33c,
title = "Toll like receptors TLR1/2, TLR6 and MUC5B as binding interaction partners with cytostatic proline rich polypeptide 1 in human chondrosarcoma",
abstract = "Metastatic chondrosarcoma is a bone malignancy not responsive to conventional therapies; new approaches and therapies are urgently needed. We have previously reported that mTORC1 inhibitor, antitumorigenic cytostatic proline rich polypeptide 1 (PRP-1), galarmin caused a significant upregulation of tumor suppressors including TET1/2 and SOCS3 (known to be involved in inflammatory processes), downregulation of oncoproteins and embryonic stem cell marker miR-302C and its targets Nanog, c-Myc and Bmi-1 in human chondrosarcoma. To understand better the mechanism of PRP-1 action it was very important to identify the receptor it binds to. Nuclear pathway receptor and GPCR assays indicated that PRP-1 receptors are not G protein coupled, neither do they belong to family of nuclear or orphan receptors. In the present study, we have demonstrated that PRP-1 binding interacting partners belong to innate immunity pattern recognition toll like receptors TLR1/2 and TLR6 and gel forming secreted mucin MUC5B. MUC5B was identified as PRP-1 receptor in human chondrosarcoma JJ012 cell line using Ligand-receptor capture technology. Toll like receptors TLR1/2 and TLR6 were identified as binding interaction partners with PRP-1 by western blot analysis in human chondrosarcoma JJ012 cell line lysates. Immunocytochemistry experiments confirmed the finding and indicated the localization of PRP-1 receptors in the tumor nucleus predominantly. TLR1/2, TLR6 and MUC5B were downregulated in human chondrosarcoma and upregulated in dose-response manner upon PRP-1 treatment. Experimental data indicated that in this cellular context the mentioned receptors had tumor suppressive function.",
keywords = "Chondrosarcoma, Galarmin, Innate immunity, MUC5B, PRP-1, Receptors, TLR1/2, TLR6",
author = "Karina Galoian and Silva Abrahamyan and Gor Chailyan and Amir Qureshi and Patel, {Part Hik} and Gil Metser and Alexandra Moran and Inesa Sahakyan and Narine Tumasyan and Albert Lee and Tigran Davtyan and Samvel Chailyan and Armen Galoyan",
year = "2018",
month = "1",
day = "1",
doi = "10.3892/ijo.2017.4199",
language = "English (US)",
volume = "52",
pages = "139--154",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - Toll like receptors TLR1/2, TLR6 and MUC5B as binding interaction partners with cytostatic proline rich polypeptide 1 in human chondrosarcoma

AU - Galoian, Karina

AU - Abrahamyan, Silva

AU - Chailyan, Gor

AU - Qureshi, Amir

AU - Patel, Part Hik

AU - Metser, Gil

AU - Moran, Alexandra

AU - Sahakyan, Inesa

AU - Tumasyan, Narine

AU - Lee, Albert

AU - Davtyan, Tigran

AU - Chailyan, Samvel

AU - Galoyan, Armen

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Metastatic chondrosarcoma is a bone malignancy not responsive to conventional therapies; new approaches and therapies are urgently needed. We have previously reported that mTORC1 inhibitor, antitumorigenic cytostatic proline rich polypeptide 1 (PRP-1), galarmin caused a significant upregulation of tumor suppressors including TET1/2 and SOCS3 (known to be involved in inflammatory processes), downregulation of oncoproteins and embryonic stem cell marker miR-302C and its targets Nanog, c-Myc and Bmi-1 in human chondrosarcoma. To understand better the mechanism of PRP-1 action it was very important to identify the receptor it binds to. Nuclear pathway receptor and GPCR assays indicated that PRP-1 receptors are not G protein coupled, neither do they belong to family of nuclear or orphan receptors. In the present study, we have demonstrated that PRP-1 binding interacting partners belong to innate immunity pattern recognition toll like receptors TLR1/2 and TLR6 and gel forming secreted mucin MUC5B. MUC5B was identified as PRP-1 receptor in human chondrosarcoma JJ012 cell line using Ligand-receptor capture technology. Toll like receptors TLR1/2 and TLR6 were identified as binding interaction partners with PRP-1 by western blot analysis in human chondrosarcoma JJ012 cell line lysates. Immunocytochemistry experiments confirmed the finding and indicated the localization of PRP-1 receptors in the tumor nucleus predominantly. TLR1/2, TLR6 and MUC5B were downregulated in human chondrosarcoma and upregulated in dose-response manner upon PRP-1 treatment. Experimental data indicated that in this cellular context the mentioned receptors had tumor suppressive function.

AB - Metastatic chondrosarcoma is a bone malignancy not responsive to conventional therapies; new approaches and therapies are urgently needed. We have previously reported that mTORC1 inhibitor, antitumorigenic cytostatic proline rich polypeptide 1 (PRP-1), galarmin caused a significant upregulation of tumor suppressors including TET1/2 and SOCS3 (known to be involved in inflammatory processes), downregulation of oncoproteins and embryonic stem cell marker miR-302C and its targets Nanog, c-Myc and Bmi-1 in human chondrosarcoma. To understand better the mechanism of PRP-1 action it was very important to identify the receptor it binds to. Nuclear pathway receptor and GPCR assays indicated that PRP-1 receptors are not G protein coupled, neither do they belong to family of nuclear or orphan receptors. In the present study, we have demonstrated that PRP-1 binding interacting partners belong to innate immunity pattern recognition toll like receptors TLR1/2 and TLR6 and gel forming secreted mucin MUC5B. MUC5B was identified as PRP-1 receptor in human chondrosarcoma JJ012 cell line using Ligand-receptor capture technology. Toll like receptors TLR1/2 and TLR6 were identified as binding interaction partners with PRP-1 by western blot analysis in human chondrosarcoma JJ012 cell line lysates. Immunocytochemistry experiments confirmed the finding and indicated the localization of PRP-1 receptors in the tumor nucleus predominantly. TLR1/2, TLR6 and MUC5B were downregulated in human chondrosarcoma and upregulated in dose-response manner upon PRP-1 treatment. Experimental data indicated that in this cellular context the mentioned receptors had tumor suppressive function.

KW - Chondrosarcoma

KW - Galarmin

KW - Innate immunity

KW - MUC5B

KW - PRP-1

KW - Receptors

KW - TLR1/2

KW - TLR6

UR - http://www.scopus.com/inward/record.url?scp=85035359497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035359497&partnerID=8YFLogxK

U2 - 10.3892/ijo.2017.4199

DO - 10.3892/ijo.2017.4199

M3 - Article

C2 - 29138803

AN - SCOPUS:85035359497

VL - 52

SP - 139

EP - 154

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 1

ER -